Zacks.com on MSN16h
AbbVie Stock Falls 11% in a Month: Should You Buy the Dip?AbbVie’s ABBV stock declined almost 11% in the past month, mainly due to a recent pipeline setback. In November, AbbVie ...
AbbVie said two trials investigating emraclidine as a once-daily, oral monotherapy treatment for adults with schizophrenia ...
At the start of 2023, U.S. patent exclusivity expired for the blockbuster drug Humira, AbbVie's chief cash cow. During the 20 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback